Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02881008
Other study ID # MYR 201 (HBV)
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date November 14, 2012
Est. completion date October 4, 2014

Study information

Verified date December 2017
Source Hepatera Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.


Description:

This is a randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B. Accounting for screen-outs about 76 patients will be screened and 48 of them will be randomized into 6 treatment groups:

Arm A (8 patients): Myrcludex B 0.5 mg / day / sc / 12 weeks Arm B (8 patients): Myrcludex B 1 mg / day / sc / 12 weeks Arm C (8 patients): Myrcludex B 2 mg / day / sc / 12 weeks Arm D (8 patients): Entecavir 0.5 mg / day / orally / 24 weeks Arm E (8 patients): Myrcludex B 5 mg / day / sc / 12 weeks Arm F (8 patients): Myrcludex B 10 mg / day / sc / 24 weeks

The study consists of screening period up to 28 days (Day -28 -1); baseline visit (Day 0), treatment period up to 12 weeks for groups A-C, E and 24 weeks for groups D, F; follow-up period up to 12 weeks for groups A-C, E, F.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date October 4, 2014
Est. primary completion date October 4, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Age 18-65 years inclusive at the time of giving of written informed consent for study participation.

2. Chronic hepatitis B defined by the presence of HBsAg for at least 6 months prior to screening period.

3. Liver biopsy performed within one year prior to screening or during screening period.

4. Alanine aminotransferase (ALT) =1.5 x ULN and = 6 x ULN. If ALT level during screening period is =1 ULN the patient can be included in the study after obtaining the sponsor's approval and if the following conditions are met :

- evidence of inflammation such as lymphocyte infiltration confirmed by liver biopsy performed within the 6 months prior to the inclusion in the study,

- and/or the patient has a history of elevated ALT levels of =1.5 ULN during the 12 months prior to screening period.

5. HBeAg negative and anti-HBeAg positive.

6. HBV DNA = 104 copies/mL.

7. All women of childbearing potential must have a negative urine pregnancy test prior to enrolment.

8. Women must:

- Be menopausal for at least 2 years, or

- Be surgically sterile (total hysterectomy or bilateral ovariectomy or bilateral tubal ligation/clips or otherwise be incapable of pregnancy), or

- Not be heterosexually active during the study, or

- Agree to use a highly effective method of birth control (double barrier method or combination of barrier method with hormonal or intrauterine device) during the study and for 3 month after the last dosing of the investigational medicinal product.

9. Men must agree to use a highly effective method of birth control (double barrier methods or combination of barrier method with hormonal or intrauterine device in their women-partner) and not to donate a sperm during the study and for 3 month after the last dosing of the investigational medicinal product.

10. An understanding, ability and willingness to fully comply with study procedures and restrictions.

11. An ability to provide the written informed consent to participate in the study.

Exclusion Criteria:

1. Decompensated liver disease (Child-Pugh-Score >6).

2. Any sign of liver cirrhosis (histological, ultra sound, biochemical).

3. Co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV.

4. ALT > 6 ULN.

5. Creatinine clearance < 60 mL/min.

6. Total bilirubin > 2 mg/dL.

7. Pre-treatment with nucleoside-analogues (lamivudine, telbivudine, entecavir) less than 6 months prior to the first dosing of the investigational medicinal products. Pre-treatment with nucleotide-analogues and interferons is allowed.

8. History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies or elevated serum alpha-fetoprotein (AFP) levels. In patients with such findings, HCC will be ruled-out prior to screening for the present study.

9. One or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, e.g. congestive heart failure or other severe cardiopulmonary disease). Patients with Gilbert's syndrome and Dubin-Johnson syndrome, two benign disorders associated with low-grade hyperbilirubinemia can be enrolled into the trial.

10. History of clinically evident pancreatitis.

11. History of alcohol or drug abuse within the preceding two years. For the purposes of the present study, alcohol abuse is arbitrarily defined as frequent consumption of alcoholic beverages with an average daily intake of more than 40 g of ethanol.

12. Participation in another study with an investigational drug within less than one month prior to this study or simultaneously to this study.

13. Patients who are unable or unwilling to follow the protocol requirements.

14. Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator.

15. Patients with limited mental capacity to the extent that she/he cannot provide informed consent or information regarding adverse events of the study drug.

16. Clinically significant renal, respiratory or cardiovascular disease.

17. Pregnancy and lactation.

18. Patients who have previously participated in this study.

Study Design


Intervention

Drug:
Entecavir

Myrcludex B


Locations

Country Name City State
Russian Federation SBEI of Higher Professional Education "South Ural State Medical university" of the MoH of the RF Chelyabinsk
Russian Federation 1-st MMU n.a. I.M. Sechenov based in Moscow State-Owned Health Care Institution "Infectious Clinical Hospital ? 2 of Moscow Healthcare Department" Moscow
Russian Federation FSBHI "Central Clinical Hospital RAS" Moscow
Russian Federation FSBI of Higher Education "People's Friendship University" Moscow
Russian Federation LLC "Clinical Hospital of Tsentrosoyuz" Moscow
Russian Federation SPb SBHI "The Center for Prevention and Control of AIDS and Infectious Diseases" Saint Petersburg
Russian Federation SPb SIH "Clinical Centre of Infectious Diseases Named After S.P. Botkin" Saint Petersburg
Russian Federation Medical Company "Hepatolog" LLC Samara
Russian Federation SBIH "Stavropol Regional Clinical Hospital" Stavropol'

Sponsors (1)

Lead Sponsor Collaborator
Hepatera Ltd.

Country where clinical trial is conducted

Russian Federation, 

References & Publications (6)

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004 Mar;11(2):97-107. Review. — View Citation

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190. — View Citation

Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402. — View Citation

Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003 Apr;83(2):633-71. Review. — View Citation

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012 Nov 13;1:e00049. doi: 10.7554/eLife.00049. Erratum in: Elife. 2014;3:e05570. — View Citation

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012 Nov 13;3. doi: 10.7554/eLife.00049. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Patients With HBsAg Response at 12 Week of Therapy HBsAg response is defined as serum HBsAg decline of at least 0.5 logs IU/ml (or HBsAg negativation) at week 12 compared to baseline. 12 week
Secondary Proportion of Patients With HBsAg Response at 24 Week of Therapy HBsAg response is defined as serum HBsAg decline of at least 0.5 logs IU/ml (or HBsAg negativation) at week 24 compared to baseline. 24 weeks
Secondary Proportion of Patients With HBV DNA Response at Week 12 of Therapy HBV DNA response is defined as persistent reduction of HBV DNA by >1 log IU/ml or negativation at week 12 compared to baseline. 12 weeks
Secondary Proportion of Patients With Biochemical Response at 12 Weeks of Therapy Biochemical response is defined as normalization of ALT level at week 12 compared to baseline. 12 weeks
Secondary Proportion of Patients With cccDNA Response at 24 Week of Therapy Virological cccDNA response is defined as reduction of intrahepatic cccDNA by 0.5 logs in comparison to baseline at week 24. 24 weeks
Secondary Proportion of Patients With HBV DNA Response at Week 24 of Therapy HBV DNA response is defined as persistent reduction of HBV DNA by >1 log IU/ml or negativation at week 24 compared to baseline. 24 weeks
Secondary Proportion of Patients With Biochemical Response at 24 Weeks of Therapy Biochemical response is defined as normalization of ALT level at week 24 compared to baseline. 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A